Being a potent inhibitor of CDK2/CDK5, (S)-PHA533533 was developed as an anti-tumor drug and has been previously preclinically tested by administrating 7.5 mg/kg orally into a human ovarian A2780 xenograft mouse model twice a day for 20 days without any signs of toxicity24. This evidence concerns the gene CDK5 and neoplasm.